Barclays’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-700,000
Closed -$3.29M – 5400
2026
Q1
$3.29M Buy
+700,000
New +$3.55M ﹤0.01% 2068

Other funds holding CTMX

Barclays's CTMX Position: Q3 2026 in Review

Barclays increased its CytomX Therapeutics (CTMX) stake by 349% in Q3 2026, buying an estimated $1.47M and bringing the position to 568,003 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2759.

Barclays first reported a position in CTMX in Q4 2015 and has held it in 31 quarters since. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Barclays held 568,003 shares of CytomX Therapeutics worth $1.54M as of Q3 2026.
  • Barclays bought 441,588 CytomX Therapeutics shares in Q3 2026, an estimated $1.47M.
  • CytomX Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2759 holding.
  • Barclays first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 31 quarters since.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.